MiR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients.

ABSTRACT: Non-small-cell lung cancer (NSCLC) is the most common malignancy worldwide. Platinum-based chemotherapy is the standard of care for these patients. Recent research showed that miR-7 methylation status is a biomarker of cisplatin resistance in lung and ovarian cancer cells, which is one of the major limitations associated with their clinical management. The aim of the present study is to provide clinical insights associated with this novel potential biomarker in NSCLC patients by comparing the miR-7 methylation status with the cisplatin treatment response. Our results analyzed in 81 samples show that miR-7 methylation is a common event in tumor tissue and it is more frequent as the stage of the disease advances, remaining in 75% of metastatic patients. Tumor miR-7 unmethylation trend to a b

SUBMITTER: Rodriguez-Antolin C 

PROVIDER: S-EPMC6686393 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature